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Comparison of transplant efficiency between spontaneously derived and
noggin-primed human embryonic stem cell neural precursors in the
quinolinic acid rat model of Huntington's disease
Abstract

Human neural precursors (hNP) derived from embryonic stem cells (hESC) may provide a viable cellular
source for transplantation therapy for Huntington's disease (HD). However, developing effective
transplantation therapy for the central nervous system (CNS) using hESC relies on optimizing the in vitro
production of hNP to control appropriate in vivo posttransplantation neuronal differentiation. The current
study provides the first direct in vivo comparison of the transplant efficiency and posttransplantation
characteristics of spontaneously derived and noggin-primed hNP following transplantation into the
quinolinic acid (QA) rat model of HD. We show that spontaneously derived and noggin-primed hNP both
survived robustly up to 8 weeks after transplantation into the QA-lesioned striatum of the adult rat.
Transplanted hNP underwent extensive migration and large-scale differentiation towards a predominantly
neuronal fate by 8 weeks post-transplantation. Furthermore, in vitro noggin priming of hNP specifically
increased the extent of neuronal differentiation at both 4 and 8 weeks posttransplantation when compared to
spontaneously derived hNP grafts. The results of this study suggest that in vit ro noggin priming provides an
effective mechanism by which to enhance hNP transplant efficiency for the treatment of HD.
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Brief Communication

Comparison of Transplant Efficiency Between Spontaneously
Derived and Noggin-Primed Human Embryonic Stem Cell Neural
Precursors in the Quinolinic Acid Rat Model of Huntington’s Disease
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Martin F. Pera,¶ Malcolm Horne,‡§ and Bronwen Connor*
*Department of Pharmacology and Clinical Pharmacology, FMHS, University of Auckland, Auckland, New Zealand
†Centre for Neuroscience and Department of Pharmacology, University of Melbourne, Parkville, Australia
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University of Southern California, Los Angeles, CA, USA

Human neural precursors (hNP) derived from embryonic stem cells (hESC) may provide a viable cellular
source for transplantation therapy for Huntington’s disease (HD). However, developing effective transplantation therapy for the central nervous system (CNS) using hESC relies on optimizing the in vitro production
of hNP to control appropriate in vivo posttransplantation neuronal differentiation. The current study provides
the first direct in vivo comparison of the transplant efficiency and posttransplantation characteristics of
spontaneously derived and noggin-primed hNP following transplantation into the quinolinic acid (QA) rat
model of HD. We show that spontaneously derived and noggin-primed hNP both survived robustly up to 8
weeks after transplantation into the QA-lesioned striatum of the adult rat. Transplanted hNP underwent
extensive migration and large-scale differentiation towards a predominantly neuronal fate by 8 weeks posttransplantation. Furthermore, in vitro noggin priming of hNP specifically increased the extent of neuronal
differentiation at both 4 and 8 weeks posttransplantation when compared to spontaneously derived hNP
grafts. The results of this study suggest that in vitro noggin priming provides an effective mechanism by
which to enhance hNP transplant efficiency for the treatment of HD.
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INTRODUCTION

proof-of-principle evidence of neuroanatomical integration that alleviates clinically relevant motor and cognitive deficits (5,6,9–11,14,20,23,24,28,29,36). As a result,
primary fetal tissue transplantation for HD is currently
undergoing clinical evaluation (2,3,12,13,15–18,22,31–33).
However, ethical and technical issues associated with
the use of primary fetal tissue for cell transplantation
therapy have prompted studies to evaluate the potential
of alternative renewable cell sources for transplantation
therapy. Recent studies have identified the therapeutic
value of various types of stem/progenitor cell transplants

Huntington’s disease (HD) is an autosomal dominant
genetic neurodegenerative disorder (19) characterized by
involuntary movements, cognitive deficits, and behavioral changes due to the progressive and selective degeneration of striatal GABAergic medium spiny projection
neurons. HD is a good candidate for cell transplantation
therapy because there is no effective treatment and there
is the potential for early intervention. Primary fetal cells
grafted into animal models of HD have demonstrated
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for HD (29,39,40). In particular, human embryonic stem
cells (hESC) have the potential to provide a stable and
unlimited cell source for transplantation therapy (35).
The feasibility of transplanting hESC into the central
nervous system (CNS) relies on the in vitro production
of neural precursors (hNP). There are several methods
for deriving hNP from hESC (1,21,27,30,37) but the
transplant efficiency and posttransplantation characteristics of hNP derived with these methods have not been
compared under the same in vivo conditions. One of the
original methods for deriving NP from hESC relied on
the spontaneous generation of rosette-like structures in
differentiated colonies of hESC (30). Pera and colleagues (26) advanced this technique by the development of an efficient and controlled serum-free method
for deriving hNP-rich cultures from hESC by priming
cultures through the addition of the bone morphogenic
protein antagonist noggin. Noggin-induced hNP can be
maintained as free-floating neurospheres that differentiate in vitro into astrocytes, oligodendrocytes, and electrophysiologically mature neurons (21,26). In the current
study we use both spontaneous derivation in neural medium (30) and noggin-primed derivation (21) to induce
hNP from hESC. Transplant efficiency and posttransplantation characteristics of hNP derived from each
method were directly compared in vivo using the quinolinic acid (QA) lesion model of HD.
MATERIALS AND METHODS
The GFP-expressing hESC line ENVY (7) was used
for posttransplantation identification of hNP. This line
expresses GFP at sustained, high levels throughout the
entire cell in all differentiated progeny. ENVY hNPs
were derived either by noggin treatment (500 ng/ml) of
hESC (8) or by spontaneous hESC differentiation (30).
In both conditions, rosette structures were mechanically
harvested and cultured in suspension in neural medium
supplemented with growth factors to allow neurospheres
formation as previously described (30). hESC-derived
neurospheres were cultured for 3 weeks prior to the day
of transplantation, upon which they were collected, gently dissociated using Cell Dissociation Buffer (Invitrogen), and suspended in neurobasal medium without growth
factors at 37,500 cells/µl for transplantation. All experiments were performed in strict compliance with the Florey Neuroscience Institute Animal Ethics Guidelines and
conformed to international guidelines on the ethical use
of animals.
Adult male Wistar rats (250–300 g at QA lesion) received surgery under IP anesthesia using 0.1 ml/kg of a
7:3 mix of ketamine (100 mg/ml) and xylazine (20 mg/
ml). Transplantation of 2 µl/site of hNPs across two
sites in the striatum (relative to bregma: AP +0.7 mm
and ML +2.5 mm, DV −5.0 mm and −4.0 mm) was
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undertaken 1 week after 50 nM QA lesioning (at coordinates AP +0.5 mm, ML +2.7 mm, DV −5.0 mm).
Cyclosporine (10 mg/kg, SC) was administered three
times weekly for the duration of the experiment beginning 48 h prior to transplantation. Animals were transcardially perfused with 4% paraformaldehyde after terminal anesthesia with sodium pentobarbitone (120 mg/
kg, IP) either 4 (n = 8) or 8 (n = 9) weeks after transplantation, brains were then postfixed in 4% paraformaldehyde overnight before further processing.
Brains were cryoprotected in 30% sucrose and sectioned on a Microm HM450 sliding microtome set at 40
µm. Eight series of sections (320 µm between consecutive sections within a series) were collected and stored
in cryoprotective solution at −20°C. For immunofluorescence, sections were incubated with the appropriate primary antibodies. Antibodies were used at the following
concentrations: mouse anti-MAP2 1:1000 (Millipore,
USA), mouse anti-Pax6-s 1:20 (Developmental Studies
Hybridoma Bank, IA, USA) mouse anti-NeuN 1:500
(Millipore), rabbit anti-GFAP 1:500 (DAKO, Sweden),
rabbit anti-DARPP-32 1:500 (Millipore), rabbit antiGAD67 1:1000 (Millipore), mouse anti-Ki67 1:200
(MIB-1 clone, DAKO), and mouse anti-Oct3/4 1:40
(Santa Cruz). Secondary goat anti-rabbit and goat antimouse Alexa FluorTM 594 antibodies (1:200, Invitrogen)
were used. Fluorescently labeled sections were imaged
using a confocal laser-scanning microscope (Leica TCS
SP2) equipped with UV, argon, argon/krypton and helium/neon lasers (Biomedical Imaging Resource Unit,
University of Auckland).
GFP and the fluorescent labels were imaged serially
to eliminate detection of bleed through and other artifactual fluorescence. To confirm colocalization confocal
images were captured in a Z-series with an interslice gap
of 0.3 µm. Graft volume was quantified from a set of
serial coronal sections (distance 320 µm) from each animal. Graft core GFP expression was analyzed using
Stereo InvestigatorTM (Microbrightfield, Williston, VT,
USA) linked to a Nikon e800 upright microscope with
epiflourescent capabilities. All statistical analysis was
undertaken using Graphpad Prism v4.02 (Graphpad
Software Inc., CA, USA). Analysis between groups at
the same time point was undertaken using two-tailed unpaired Student’s t-tests, whereas comparisons between
multiple groups at different time points were undertaken
using two-way ANOVA analysis with Bonferroni post
hoc analysis. All results are presented as mean ± SEM
and deemed statistically significant if p < 0.05.
RESULTS
Both spontaneously derived and noggin-primed ENVY
hNPs transplants produced robust dense graft cores in
the QA-lesioned striatum that survived up to 8 weeks
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posttransplantation (Fig. 1A, B). Occasional GFP-positive hNPs were observed to extend up the needle tract
and into the ipsilateral cortex (boxed region in Fig. 1A).
Human nuclei staining confirmed that grafts expressing
GFP were of human origin (Fig. 1C). Grafts were present in 7/8 recipient rats at 4 weeks posttransplantation
and 7/9 recipient rats by 8 weeks posttransplantation;
overall grafts survived in 14/17 of transplanted rats. By
8 weeks posttransplantion, 1/4 of the spontaneously derived hNPs grafts had developed into a large hyperplasic
growth. The severely hyperplasic spontaneously derived
hNP graft in the 8 week cohort compressed the ventricle
walls and contained intragraft rosettes (Fig. 1D). This
excessive overgrowth was not seen in any of the nogginprimed grafts, suggesting that highly proliferative cells
remained in the neurospheres of spontaneously derived
hNP even after 3 weeks induction in neural medium.
Within the hyperplasic growth Oct3/4-positive pluripotent hESC (Fig. 1E) and a large numbers of human
Ki67-positive proliferating cells (Fig. 1F) were found.
The animal with spontaneously derived hNP that formed
severe hyperplasia was excluded from subsequent analyses.
Epifluorescence microscopy and the Microbrightfield
Stereo InvestigatorTM system were used to quantify the
volume of the graft core. Quantification identified that
at both 4 and 8 weeks posttransplantation, spontaneously
derived hNP grafts were larger than noggin-primed hNP
grafts (p = 0.03 and p = 0.04, respectively, two-tailed ttest) (Fig. 1G). We also observed a nonsignificant trend
for the volume of both types of graft to decrease with
time (Fig. 1G). After transplantation, GFP-positive cell
bodies from both spontaneously derived and nogginprimed grafts were found not only in the graft core at
the site of injection, but also distributed rostrocaudally
throughout the lesioned striatum with GFP-positive cells
migrating up to 3 mm from the injection site (Fig. 1H).
However, the distribution of hNP cells varied greatly
between animals and both spontaneously derived and
noggin-primed hNP were observed overall to have a
similar migratory capacity (p = 0.74, two-way ANOVA)
(Fig. 1H). In addition, GFP-positive processes were
found to extend up to 3.5 mm from the injection site in
both 4 and 8 weeks posttransplant with no difference
observed over time between transplants (p = 0.30, twoway ANOVA) (Fig. 1I).
Double fluorescent labeling and confocal microscopy
was used to identify the phenotypic fate of grafted hNP.
Cells within the striatum were randomly sampled and
analyzed for coexpression of Pax-6, NeuN, MAP2, and
GFAP. At both 4 and 8 weeks posttransplantation the
neural progenitor cell marker Pax-6 was absent from all
but a few transplanted cells in some animals (data not
shown), indicating that most grafted hNP had developed
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a mature phenotype. Analysis of expression of neuronal
markers MAP2 (Fig. 2A–C) and NeuN (Fig. 2D–F)
confirmed that grafted hNP were highly directed towards a neuronal fate after transplantation into the lesioned striatum. Many GFP-positive cells coexpressed
the neuronal marker MAP2 (isoforms a, b, and c) at both
4 and 8 weeks posttransplantation (Fig. 2A, B), with
variable staining intensity. The number and proportion
of MAP2 coexpressing cells (in both noggin-primed and
spontaneously derived transplants) increased between 4
and 8 weeks posttransplantation (p = 0.02 spontaneously
derived, p = 0.008 noggin primed) (Fig. 2C). Furthermore, in noggin-primed hNP grafts there were more
GFP-positive cells coexpressing MAP2 than in spontaneously derived hNP grafts at both 4 weeks (21.50 ±
1.71 noggin primed vs. 4.00 ± 1.78 cells per 375 µm2 of
the graft core spontaneously derived; p = 0.0004) and 8
weeks (48.00 ± 6.58 noggin primed vs. 22.75 ± 5.65
cells per 375 µm2 of the graft core spontaneously derived; p = 0.03) posttransplantation (Fig. 2C).
We also observed a population of grafted hNP differentiated into mature neurons. These cells were located
mostly at the graft/host interface and were identified by
NeuN coexpression (Fig. 2D, E). More noggin-primed
grafted hNP expressed NeuN than spontaneously derived hNP at both 4 weeks (9.50 ± 1.56 noggin primed
vs 4.00 ± 1.68 spontaneously derived cells per 375 µm2
of the graft core; p = 0.05) and 8 weeks (22.00 ± 5.22
noggin-primed vs. 6.67 ± 0.88 spontaneously derived
cells per 375 µm2 of the graft core; p = 0.04) posttransplantation (Fig. 2F). Astrocytes were also observed to
surround the edges of the ENVY hNP grafts and occasionally entered the grafts with most appearing to be
host derived. Occasionally astrocytic differentiation of
grafted hNP was seen within the main body of the
ENVY hNP grafts as demonstrated by low levels of
GFAP coexpression at 8 weeks (3.50 ± 0.65 spontaneously derived and 2.50 ± 0.65 noggin primed cells per
375 µm2 of the graft core) (Fig. 2G–I). These results
demonstrate that spontaneously derived and nogginprimed hNP undergo large-scale differentiation predominantly towards a neuronal fate by 8 weeks posttransplantation, with in vitro priming of hNP with noggin
specifically increasing the extent of neuronal differentiation. The extensive neuronal differentiation of grafted
ENVY hNP prompted a search for the expression of striatal markers that are selectively lost in animal models
of HD. However, neither DARPP-32 nor GAD67 was
coexpressed by grafted ENVY hNP in either group at 4
or 8 weeks after transplantation (data not shown).
DISCUSSION
This study has directly compared the transplant efficiency and posttransplantation characteristics of hNP de-
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Figure 1. Survival, migration, and tumor formation of transplanted ENVY hNPs in the QA-lesioned striatum. Endogenous GFP
expression in spontaneously derived (A) and noggin-primed (B) hNP grafts 8 weeks after transplantation into the QA-lesioned
striatum; boxed region in (A) denotes grafted ENVY cells in needle tract. Scale bar: 2 mm for both (A) and (B). (C) Merged
confocal image of GFP (green) and HuNu (red) coexpression confirming that GFP expression is maintained in xenotransplanted
hNPs after 8 weeks in vivo. Scale bar: 8 µm. (D) Confocal slice through hyperplasic overgrowth with characteristic rosette structures from spontaneously derived hNP graft. Scale bar: 40 µm. (E) Oct3/4 (red) and (F) Ki67 (red) expression within hyperplasic
overgrowth from a spontaneously derived hNP graft (green). Scale bar: 16 µm for both (E) and (F). (G) Graph of relative graft
core volume for noggin-primed and spontaneously derived grafts at 4 and 8 weeks posttransplantation. (H) The migration of GFPpositive cells and (I) extent of GFP-positive processes from injection site.
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Figure 2. Neural differentiation of transplanted ENVY hNP in the QA-lesioned striatum. (A, B) Representative MAP2 expression
(red) in spontaneously derived hNP grafts (A; green) and noggin-primed hNP grafts (B; green) 8 weeks after transplantation. (C)
Graph demonstrating the number of MAP2-positive hNP cells per 375 µm2 in the graft core. (D, E) Representative NeuN expression
(red) in spontaneously derived hNP grafts (D; green) and noggin-primed hNP grafts (E; green) 8 weeks after transplantation. Graph
demonstrating the number of NeuN (F) positive hNP cells per 375 µm2 in the graft core. (G, H) Representative GFAP expression
(red) in spontaneously derived hNP grafts (G; green) and noggin-primed hNP grafts (H; green) 8 weeks after transplantation. Graph
demonstrating the number of (I) GFAP-positive hNP cells per 375 µm2 in the graft core. Bonferroni post hoc pairwise comparisons.
*p < 0.05, **p < 0.01. Scale bars: 16 µm.
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rived by two different methods. We have established in
the QA-lesioned rat striatum that noggin-primed hNP
have a greater capacity to survive long term and differentiate into neurons than spontaneously derived hNP. In
addition, hyperplasic growths and aberrant differentiation was not observed to accompany grafting of nogginprimed hNP even up to 8 weeks posttransplantation,
whereas grafts of spontaneously derived hNP had the
capacity to form tumors. This suggests that noggin priming of hESC may provide an important safety advantages for hNP transplantation. We suspect this is because
noggin priming induces hNP further toward a neuronal
fate while in vitro and still within neurosphere aggregates. At the time of transplantation, spontaneously derived hNP likely comprise a more heterogeneous cell
population, including residual pluripotent cells, increasing the potential for tumor formation. Hyperplasic overgrowth of hESC derived neural grafts and teratoma formation are commonly encountered; indeed, other studies
have reported either high rates of tumor formation or
reduced rates of survival with the transplantation of extensively differentiated hESC-derived dopaminergic neurons in animal models of Parkinson’s disease (4,25,
34,38).
A small number of studies have recently been published on hESC-derived stromal cell-induced hNP transplants in animal models of HD (1,37). Song and colleagues (37) examined transplanted hNP generated by
PA6 stromal coculture up to 3 weeks posttransplantation. They reported mainly immature (nestin and TUJ1
positive) neuronal differentiation of PA6-generated hNP
following transplantation into the QA-lesioned striatum.
This is in contrast to the current study where the majority of transplanted hNP were highly neuronally directed,
and even at 4 weeks expressed mature neuronal markers,
such as MAP2 or NeuN. While Song and colleagues
(37) did not report the presence of hyperplasia, the study
did not investigate hNP cell fate beyond 3 weeks posttransplant, which may have misrepresented the potential
safety of their PA6-generated hNP. In the current study
the overgrowth and appearance of rosette-like formations was not apparent until 8 weeks posttransplantation
and was only observed in grafts of spontaneously derived hNP. Disparities between these studies may reflect
differences in cell fate determined by noggin priming of
hNP versus PA6 stromal coculture methods, and the
extent of differentiation that will be induced by longer
periods that the graft is in vivo (3 vs. 4 and 8 weeks
posttransplant). In support of this later point, a recent
investigation (1) using MS5 stromal-induced hNP
grafted into the QA-lesioned striatum found that it was
not until 8 weeks posttransplantation that significant
numbers of transplant-derived overgrowths could be
identified.
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Although ENVY hNP grafted into the QA-lesioned
striatum differentiated into mature neurons relatively
early, expression of striatal-specific markers such as
DARPP-32 expression was not observed by 8 weeks
posttransplantation. In contrast, we have previously
demonstrated that 8 weeks is sufficient for DARPP-32positive neurons to develop following the transplantation of adult rodent NP into the QA-lesioned striatum
(39). This suggests either that region-specific neuronal
phenotypes are slower to develop from xenotransplanted
hNP than in allogenic transplanted progenitors, or that
NP from embryonic stem cells are slower than those
from adult sources to develop a mature phenotypic identity. Future transplantation studies using embryonic and/
or human stem cell sources should be sure to contain an
extended period of investigation in order to confirm the
generation of region-specific striatal phenotypes.
In this study we have made the first direct comparison of the transplant efficiency and differentiation potential of spontaneously derived and noggin-primed
hESC-derived NP in the QA lesion rat model of HD. By
establishing the efficiency and safety of noggin-primed
hNPs against traditional neuronal direction paradigms in
vivo in a lesioned environment, we are able to identify
the value of larger future investigations using noggin
primed hNPs. The safety and efficiency of nogginprimed neuronal direction we have shown in the current
study decreases the likelihood of arresting future investigations due to hyperplasic hNPs, as has recently been
required in some studies (1). The assessment of spontaneously derived or noggin-primed hNPs on sensorimotor
function was not included in this current study due to
the small group sizes. However, additional long-term
studies elucidating the functional effects of nogginprimed hNP on a variety of sensorimotor deficits produced by QA striatal lesioning, and the ability for transplanted hNP to form appropriately integrated mature
medium spiny striatal neurons, will be necessary to confirm and further establish the therapeutic potential of
hESC-derived hNP transplantation for HD. The QA lesion model was used in this initial study to provide a
rapid, reliable, and well-substantiated model of the selective and extensive striatal cell loss observed in HD.
Transgenic mouse models of HD are more predictive to
the clinical situation, and future studies using transgenic
models of HD are also necessary in order to assess
whether the diseased host brain affects the long-term efficiency of hESC-derived hNP transplants.
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